We are live on ! Find out more
ZYME icon

Zymeworks

26.14 USD
-0.72
2.68%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
26.14
0.00
0%
1 day
-2.68%
5 days
-4.84%
1 month
-2.86%
3 months
-1.62%
6 months
5.23%
Year to date
-1.8%
1 year
9.74%
5 years
31.09%
10 years
101.08%
 

About: Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Employees: 264

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 26.3%
Neutral 68.4%
Negative 5.3%
Neutral
GlobeNewsWire
3 days ago
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced will participate in the following upcoming investor conferences:
Zymeworks Announces Participation in Upcoming Investor Conferences
Neutral
GlobeNewsWire
6 days ago
Zymeworks Announces $200 Million Share Repurchase Authorization
Zymeworks intends to commence the Share Repurchase Program with $140.0 million in share repurchases expected through 2028, with flexibility to adjust the pace of repurchases based on market opportunities, cash flow, and expected contribution to Total Shareholder Return (TSR) Zymeworks intends to balance capital allocation for 2027 thoughtfully across disciplined R&D pipeline development, selective M&A transactions and opportunistic share repurchases to grow underlying enterprise value while returning capital to shareholders through reducing share count over time VANCOUVER, British Columbia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a second 2026 share repurchase program under which the Company may repurchase up to $200.0 million of its outstanding common stock, par value $0.00001 per share. Zymeworks completed its initial 2026 share repurchase program under which the Company was authorized to repurchase up to $125.0 million of its outstanding common stock.
Zymeworks Announces $200 Million Share Repurchase Authorization
Negative
Zacks Investment Research
12 days ago
Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates
Zymeworks Inc. (ZYME) came out with quarterly earnings of $2.28 per share, missing the Zacks Consensus Estimate of $2.4 per share. This compares to a loss of $0.26 per share a year ago.
Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates
Neutral
GlobeNewsWire
12 days ago
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
VANCOUVER, British Columbia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2026 and provided a summary of recent business highlights. The Company has elected not to host a third quarter earnings conference call after release of its financial results.
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Positive
Zacks Investment Research
24 days ago
Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth
Zymeworks (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth
Positive
MarketBeat
25 days ago
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside
Zymeworks NASDAQ: ZYME outlined a partnering-focused research strategy, presented updated clinical data for its ZW191 antibody-drug conjugate in platinum-resistant ovarian cancer, and discussed its recently announced collaboration with Roche for the DLL3-targeting T-cell engager ZW209.
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside
Neutral
Seeking Alpha
25 days ago
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript
Neutral
Business Wire
26 days ago
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced the appointment of Adam Schayowitz, Ph.D., MBA, to its Board of Directors. Dr. Schayowitz is Executive Vice President and Head of Research and Development at Zymeworks (Nasdaq: ZYME). Dr. Schayowitz has nearly 20 years of experience in oncology drug development and has led dozens of global deve.
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Neutral
GlobeNewsWire
29 days ago
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the randomized dose-optimization portion of its ongoing Phase 1 study evaluating ZW191, a FRα-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Neutral
GlobeNewsWire
1 month ago
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that it has entered into a global license and collaboration agreement with Roche for the research, development and commercialization of ZW209, a T cell engager targeting DLL3.
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
Price charts implemented using Lightweight Charts™